Bangalore: Dishman Pharma has posted a 13.24 percent growth in the fourth quarter of FY12 and reported a consolidated net profit of Rs 312.94 million for the quarter ended 31 March, 2012, up 37.30 percent from Rs 227.92 million in the corresponding quarter last year.
Even though, the company reported flat revenues for Q4, it expects the contract research business to grow more than $15 million in FY13. Dishman Pharmaceuticals registered total consolidated income of Rs 3.50 billion for the last quarter of FY12, up 0.03 percent from the same period last year. The company has also posted consolidated net profit of Rs 568.05 million as compared to Rs 800.12 million for the Q4FY12, representing a decrease of 29 percent.
